None of the 18860 participants of the Phase 2/3 trial reported allergic reactions after either dose of the vaccine [1]. Over the entire duration of the study, o

None of the 18860 participants of the Phase 2/3 trial reported allergic reactions after either dose of the vaccine [1]. Over the entire duration of the study, one member of the treatement group suffered an anaphylactic reaction and one member of the placebo group an anaphylactic shock [2]. There is no hint that this particular vaccine is more likely to trigger allergic reactions than any other kind of medication. [1] Section 6.3.3.2.2.1. in https://www.fda.gov/media/144246/download https://www.fda.gov/media/144246/download [2] Table 23, Ibid.